EUVIMEDEUVIMED entdecken
Crossref

Local Therapy of Metastases in Colorectal Cancer: Utilization and Survival in a Nationwide Population

Mari Fjørtoft Ystgaard iD, Tor Åge Myklebust iD, Kristoffer Lassen, Halfdan Sorbye iD, Inger Kristin Larsen, Jørgen Smeby iD, Marianne G Guren, Julian Hamfjord iD

JCO Oncology Practice · 02.11.2026

DOI: 10.1200/op-26-00381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 02.11.2026. Verfasst von Mari Fjørtoft Ystgaard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Oslo University Hospital, Oslo, Norway. Die Arbeit nennt 38 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Local therapy (LT) for metastatic colorectal cancer (mCRC) is recommended when eradicating all metastases is feasible. Although LT is widely used, its population-level impact remains unclear. This study aims to use real-world population-based data to assess LT utilization and survival trends in mCRC.

Methods

Patients diagnosed with mCRC from 2010 to 2023 were included, using data from the Cancer Registry of Norway and the Norwegian Patient Registry. LT was defined as surgery, stereotactic radiotherapy (SRT), or ablation targeting liver, lung, or brain metastases. Outcomes were reported as median overall survival (OS) and 2-, 5-, and 10-year OS. The effect of the first versus last time period on survival was assessed using univariable and multivariable Cox regression.

Results

Among 64,112 CRC cases, 20,210 had mCRC. Of these, 21% received LT, 39% systemic therapy only, 12% other therapies, and 29% no therapy. Metastasectomy was the primary LT (87%), whereas SRT use was limited. LT use increased by 12% annually from 2010 to 2015 and then stabilized. The overall mCRC survival improved, with the 5-year OS increasing from 16% to 23% and the median OS from 15 to 18 months (adjusted hazard ratio, 0.92; 95% CI, 0.89 to 0.95). No significant survival improvement was observed between time periods in the LT or systemic therapy only subgroups. The 5-year OS for patients receiving LT for liver, lung, and brain metastases was 50%, 62%, and 5%, respectively.

Conclusion

LT utilization increased, with outcomes comparable with more selected populations. Survival in treatment subgroups remained stable over time, but improved in the overall mCRC population, suggesting that the population-level gains may reflect changes in treatment allocation rather than improvements within modalities.

Autor:innen und Institutionen

  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway.
  • Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway.

ORCID-Profile: Mari Fjørtoft Ystgaard, Tor Åge Myklebust, Halfdan Sorbye, Jørgen Smeby, Julian Hamfjord

Zitieren

APA

Ystgaard, M. F., Myklebust, T. Å., Lassen, K., Sorbye, H., Larsen, I. K., Smeby, J., Guren, M. G., & Hamfjord, J. (2026). Local Therapy of Metastases in Colorectal Cancer: Utilization and Survival in a Nationwide Population. JCO Oncology Practice. https://doi.org/10.1200/op-26-00381

Vancouver

Ystgaard MF, Myklebust TÅ, Lassen K, Sorbye H, Larsen IK, Smeby J, et al. Local Therapy of Metastases in Colorectal Cancer: Utilization and Survival in a Nationwide Population. JCO Oncology Practice. 2026. doi:10.1200/op-26-00381

BibTeX
@article{Ystgaard2026,
  author = {Ystgaard, Mari Fjørtoft and Myklebust, Tor Åge and Lassen, Kristoffer and Sorbye, Halfdan and Larsen, Inger Kristin and Smeby, Jørgen and Guren, Marianne G and Hamfjord, Julian},
  title = {Local Therapy of Metastases in Colorectal Cancer: Utilization and Survival in a Nationwide Population},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-26-00381}
}
Kostenlos starten →